Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers
- PMID: 20478521
- PMCID: PMC2931314
- DOI: 10.1016/j.ccr.2010.04.022
Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers
Abstract
In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen receptor, two crucial transcription factors in prostate cancer. There is an extraordinary degree of overlap between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation and promotes EZH2-mediated dedifferentiation.
(c) 2010 Elsevier Inc. All rights reserved.
Figures
Comment on
-
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018. Cancer Cell. 2010. PMID: 20478527 Free PMC article.
References
-
- Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–39. - PubMed
-
- Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–227. - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
